BMO Capital optimistic about Sage Therapeutics upcoming data readouts

BMO Capital analyst Gary Nachman kept his Outperform rating and $203 price target on Sage Therapeutics after its Q3 results, saying the company’s “much higher SG&A” spending is “supporting preparations for an expected launch of Zulresso” for postpartum depression in March of 2019. The analyst anticipates approval for Zulresso by the December PDUFA following a “very favorable AdComm last week”. Nachman is also positive on Sage Therapeutics’ development of trials for SAGE-217 in major depressive disorders, which he claims may be “an even bigger opportunity if successful”.
https://thefly.com/landingPageNews.php?id=2819035